Hereditary angioedema attacks with COVID-19 vaccination: a Canadian cross sectional analysis

Background Hereditary angioedema (HAE) is a rare disease characterized by recurrent attacks of severe swelling, driven by dysregulation of the kallikrein-kinin system. Known attack triggers include infection, stress and immune activation, raising concern that COVID-19 infection and vaccination may provoke HAE attacks. No Canadian data on this relationship is currently available. Objective To describe the relationship between COVID-19 vaccination and HAE attack frequency/severity, and to characterize patient-reported disease control through the pandemic in a Canadian HAE cohort. Methods A descriptive cross-sectional survey was distributed (March 2020–December 2023) to members of the Hereditary Angioedema Canada and Angio-oedeme Hereditaire Quebec. Participants reported demographics, vaccination history, HAE attack frequency/severity/timing, prophylaxis use, and Hereditary Angioedema Activity Score (HAE-AS) for 6-month periods pre-pandemic and post-vaccination. Results Of 400 patients invited, 51 completed surveys were analyzed (12.5% response rate). Most respondents were female (78%), diagnosed > 5 years (78%), and on long-term prophylaxis (84%), primarily lanadelumab. HAE-AS scores remained stable across vaccination periods. Nine patients (mostly on prophylaxis) reported an HAE attack within 72 h of vaccination (mostly mRNA), generally mild-to-moderate, with no urgent care visits or treatment changes. Five patients declined vaccination, three citing fear of triggering an attack. Conclusion Canadian patients with HAE reported stable disease activity and low rates of severe vaccine-related attacks throughout the COVID-19 pandemic, alongside low vaccine hesitancy, though high baseline prophylaxis use may limit generalizability. Clinical Implication COVID-19 vaccination, including mRNA formulations, appears generally safe for HAE patients, particularly those on long-term prophylaxis. This observation supports continued adherence to routine vaccine recommendations while highlighting the need for patient counseling to address attack-related vaccine hesitancy.

Authors

Institutions

Publication Details

Journal
Allergy Asthma and Clinical Immunology
Published
2026-11-19
DOI
https://doi.org/10.1186/s13223-026-01086-2
Primary Topic
Coagulation, Bradykinin, Polyphosphates, and Angioedema
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hereditary angioedema attacks with COVID-19 vaccination: a Canadian cross sectional analysis

Amin S. Kanani, Gina Lacuesta, Rozita Borici‐Mazi, Susan Waserman et al.
Allergy Asthma and Clinical Immunology
Coagulation, Bradykinin, Polyphosphates, and Angioedema
article

Hereditary angioedema attacks with COVID-19 vaccination: a Canadian cross sectional analysis

Amin S. Kanani, Gina Lacuesta, Rozita Borici‐Mazi, Susan Waserman, Stephen Betschel, Paul Kevin Keith, Chrystyna Kalicinsky, Victoria E. Cook, Tess Robart
article en

Abstract

Background Hereditary angioedema (HAE) is a rare disease characterized by recurrent attacks of severe swelling, driven by dysregulation of the kallikrein-kinin system. Known attack triggers include infection, stress and immune activation, raising concern that COVID-19 infection and vaccination may provoke HAE attacks. No Canadian data on this relationship is currently available. Objective To describe the relationship between COVID-19 vaccination and HAE attack frequency/severity, and to characterize patient-reported disease control through the pandemic in a Canadian HAE cohort. Methods A descriptive cross-sectional survey was distributed (March 2020–December 2023) to members of the Hereditary Angioedema Canada and Angio-oedeme Hereditaire Quebec. Participants reported demographics, vaccination history, HAE attack frequency/severity/timing, prophylaxis use, and Hereditary Angioedema Activity Score (HAE-AS) for 6-month periods pre-pandemic and post-vaccination. Results Of 400 patients invited, 51 completed surveys were analyzed (12.5% response rate). Most respondents were female (78%), diagnosed > 5 years (78%), and on long-term prophylaxis (84%), primarily lanadelumab. HAE-AS scores remained stable across vaccination periods. Nine patients (mostly on prophylaxis) reported an HAE attack within 72 h of vaccination (mostly mRNA), generally mild-to-moderate, with no urgent care visits or treatment changes. Five patients declined vaccination, three citing fear of triggering an attack. Conclusion Canadian patients with HAE reported stable disease activity and low rates of severe vaccine-related attacks throughout the COVID-19 pandemic, alongside low vaccine hesitancy, though high baseline prophylaxis use may limit generalizability. Clinical Implication COVID-19 vaccination, including mRNA formulations, appears generally safe for HAE patients, particularly those on long-term prophylaxis. This observation supports continued adherence to routine vaccine recommendations while highlighting the need for patient counseling to address attack-related vaccine hesitancy.

Allergy Asthma and Clinical Immunology
Dalhousie University (CA), University of British Columbia (CA), University of Toronto (CA), University of Victoria (CA), University of Manitoba (CA), McMaster University (CA)
Coagulation, Bradykinin, Polyphosphates, and Angioedema
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon